Fei Liu

This inventor holds 18 USPTO granted patents and 8 published patent applications and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Centaurus Biopharma Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fei Liu. Retrieved from https://idiyas.com/inventor/fei-liu-k6sw1hht

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 8)

% Patents Active = 77.8

EPO Patents = 12 (Patent Applications = 23)

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Jiangsu, CN (2013 - 2022)
Lianyungang, CN (2018 - 2023)

Company Filing History:

16 out of 121

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

8 out of 33

Centaurus Biopharma Co., Ltd.

patents

5 out of 26

Lianyungang Runzhong Pharmaceutical Co., Ltd.

patents

4. 1 out of 12

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

5. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

BCL-2 Inhibitor

Crystalline Compounds

Sulfonamide

Quinolone Derivatives

c-Met Kinase Inhibitor

DPP-IV Inhibitors

Aminopyrazole

Pyrimidine

Quinazoline Derivative

Thiadiazole

Trifluoromethyl

Pyridone

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12545674 - Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor (2026-02-10),

2. 12371431 - Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor (2025-07-29),

3. 12358913 - Crystal of diarylthiohydantoin compound (2025-07-15),

4. 12358891 - Crystals of quinolone derivatives (2025-07-15),

5. 12319689 - Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor (2025-06-03),

6. 12187710 - Salt of Syk inhibitor and crystalline form thereof (2025-01-07),

7. 11773079 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine (2023-10-03),

8. 11279676 - Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof (2022-03-22),

9. 11098060 - Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof (2021-08-24),

10. 11021464 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt (2021-06-01),

11. 10858340 - Crystal of salt of quinazoline derivative (2020-12-08),

12. 10851071 - M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof (2020-12-01),

13. 10501468 - Method for preparing intermediate of 6-arylaminopyridonecarboxamide compound as MEK inhibitor (2019-12-10),

14. 10450328 - Crystals of thiadiazole derivative DPP-IV inhibitors and uses thereof (2019-10-22),

15. 10376512 - Crystal of aniline pyrimidine compound of trifluoroethyl substituted indole and salt thereof (2019-08-13),

Title: The Innovative Journey of Inventor Fei Liu

Introduction: Fei Liu is a prominent inventor based in Lianyungang, China, known for his groundbreaking contributions to the field of medicine. With a total of 17 patents to his name, Liu has developed innovative compounds aimed at addressing critical health issues, especially in the realm of cancer treatment and androgen-mediated diseases.

Latest Patents: Among his latest patents is the "Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor." This patent discloses a compound that serves as a selective inhibitor for the BCL-2 protein, which is pivotal in treating anti-apoptotic BCL-2-related diseases, such as cancer. The patent includes details on the compound's formula, pharmaceutical composition, and its application in therapies. Another significant patent is related to a "Crystal of diarylthiohydantoin compound," which highlights a preparation method for this compound and its use in developing medicaments for diseases linked to androgen.

Career Highlights: Liu's career has been marked by his impressive work with notable pharmaceutical companies, including Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Centaurus Biopharma Co., Ltd. His efforts in drug development and innovation have positioned him as a key player in his field, contributing significantly to advancements in pharmaceutical sciences.

Collaborations: Throughout his career, Liu has collaborated with talented individuals, including Xiquan Zhang and Yizhong Zhu. These partnerships have fostered a creative environment that has led to the successful development of complex medicinal compounds designed to combat significant health challenges.

Conclusion: Fei Liu's innovative spirit and dedication to advancing medical science through his patents are commendable. His work not only reflects a commitment to innovation but also showcases the potential of scientific inquiry in developing effective treatments. As he continues to explore new frontiers in medicine, Liu remains a valuable asset to the field and an inspiration to aspiring inventors.

Profile summary based on public USPTO records.